Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01595438 · ClinicalTrials.gov registry record · Phase 3
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 598
- Enrollment target
NCT01595438 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 598 participants.
The verdict
NCT01595438, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 598 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis
Interventions
- DRUG Ceftazidime - Avibactam ( CAZ-AVI)
- DRUG Doripenem
- DRUG Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
- DRUG or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 598 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01595438
The ClinicalTrials.gov registry entry for NCT01595438 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 598 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ceftazidime - Avibactam ( CAZ-AVI) is the first listed.
NCT01595438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01595438 about?
NCT01595438 is a clinical study titled "Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)". The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis
What is the current status of trial NCT01595438?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 598 participants. The study started on 2012-10. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01595438?
The interventions under investigation include: Ceftazidime - Avibactam ( CAZ-AVI) (DRUG), Doripenem (DRUG), Either switch to oral therapy: 500 mg of Ciprofloxacin (oral) (DRUG), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral) (DRUG).
Who is sponsoring clinical trial NCT01595438?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.